Progression-related expression of β3 integrin in melanomas and nevi

Patricia A. Van Belle, Rosalie Elenitsas, Kapaettu Satyamoorthy, Jonathan T. Wolfe, Dupont Guerry IV, Lynne Schuchter, Timothy J. Van Belle, Stephen Albelda, Paulo Tahin, Meenhard Herlyn, David E. Elder

    Research output: Contribution to journalArticle

    99 Citations (Scopus)

    Abstract

    The expression of the βs integrin subunit was investigated in 130 fixed, paraffin-embedded specimens of human melanomas and nevi using two different monoclonal antibodies. Expression was not observed in melanocytes and was absent or low in most nevi. In primary melanomas, expression was absent or low in the nontumorigenic radial growth phase, which includes the classes of in situ and microinvasive melanomas. In contrast, expression was high in the tumorigenic or vertical growth phase compartment of many primary melanomas and in most metastatic melanomas. Expression patterns were similar with the two antibodies, SSA6 and SAP, and was membrane-related as well as cytoplasmically expressed. In those nevi that reacted locally, the reactivity tended to occur in the dermal component of necrotized nevi, and in Spitz nevi, where the reactivity was stronger and more diffuse. A few dysplastic nevi showed focal reactivity of the junctional component. These results are consistent with tumor progression-related expression of the β3 integrin, which is expressed in melanocytic tumors as the αvβ3 integrin, having affinity for matrix molecules, including vitronectin and fibronectin. In all melanomas, and in the subset of tumorigenic vertical growth phase melanomas, expression increased with thickness (P < .01). For this reason, and because ligation of this integrin has been shown in vitro to have several properties that may be related to the malignant phenotype, it is likely that expression of this marker may hove prognostic value. However, because of its consistent and strong expression in Spitz nevi, the diagnostic utility of this marker will likely be limited.

    Original languageEnglish
    Pages (from-to)562-567
    Number of pages6
    JournalHuman Pathology
    Volume30
    Issue number5
    DOIs
    Publication statusPublished - 1999

    Fingerprint

    Nevi and Melanomas
    Integrins
    Melanoma
    Nevus
    Epithelioid and Spindle Cell Nevus
    Growth
    Dysplastic Nevus Syndrome
    Vitronectin
    Melanocytes
    Fibronectins
    Paraffin
    Ligation
    Neoplasms
    Monoclonal Antibodies
    Phenotype
    Skin
    Membranes
    Antibodies

    All Science Journal Classification (ASJC) codes

    • Pathology and Forensic Medicine

    Cite this

    Van Belle, P. A., Elenitsas, R., Satyamoorthy, K., Wolfe, J. T., Guerry IV, D., Schuchter, L., ... Elder, D. E. (1999). Progression-related expression of β3 integrin in melanomas and nevi. Human Pathology, 30(5), 562-567. https://doi.org/10.1016/S0046-8177(99)90202-2
    Van Belle, Patricia A. ; Elenitsas, Rosalie ; Satyamoorthy, Kapaettu ; Wolfe, Jonathan T. ; Guerry IV, Dupont ; Schuchter, Lynne ; Van Belle, Timothy J. ; Albelda, Stephen ; Tahin, Paulo ; Herlyn, Meenhard ; Elder, David E. / Progression-related expression of β3 integrin in melanomas and nevi. In: Human Pathology. 1999 ; Vol. 30, No. 5. pp. 562-567.
    @article{28786485a59b4f0283f293a7b20dad17,
    title = "Progression-related expression of β3 integrin in melanomas and nevi",
    abstract = "The expression of the βs integrin subunit was investigated in 130 fixed, paraffin-embedded specimens of human melanomas and nevi using two different monoclonal antibodies. Expression was not observed in melanocytes and was absent or low in most nevi. In primary melanomas, expression was absent or low in the nontumorigenic radial growth phase, which includes the classes of in situ and microinvasive melanomas. In contrast, expression was high in the tumorigenic or vertical growth phase compartment of many primary melanomas and in most metastatic melanomas. Expression patterns were similar with the two antibodies, SSA6 and SAP, and was membrane-related as well as cytoplasmically expressed. In those nevi that reacted locally, the reactivity tended to occur in the dermal component of necrotized nevi, and in Spitz nevi, where the reactivity was stronger and more diffuse. A few dysplastic nevi showed focal reactivity of the junctional component. These results are consistent with tumor progression-related expression of the β3 integrin, which is expressed in melanocytic tumors as the αvβ3 integrin, having affinity for matrix molecules, including vitronectin and fibronectin. In all melanomas, and in the subset of tumorigenic vertical growth phase melanomas, expression increased with thickness (P < .01). For this reason, and because ligation of this integrin has been shown in vitro to have several properties that may be related to the malignant phenotype, it is likely that expression of this marker may hove prognostic value. However, because of its consistent and strong expression in Spitz nevi, the diagnostic utility of this marker will likely be limited.",
    author = "{Van Belle}, {Patricia A.} and Rosalie Elenitsas and Kapaettu Satyamoorthy and Wolfe, {Jonathan T.} and {Guerry IV}, Dupont and Lynne Schuchter and {Van Belle}, {Timothy J.} and Stephen Albelda and Paulo Tahin and Meenhard Herlyn and Elder, {David E.}",
    year = "1999",
    doi = "10.1016/S0046-8177(99)90202-2",
    language = "English",
    volume = "30",
    pages = "562--567",
    journal = "Human Pathology",
    issn = "0046-8177",
    publisher = "W.B. Saunders Ltd",
    number = "5",

    }

    Van Belle, PA, Elenitsas, R, Satyamoorthy, K, Wolfe, JT, Guerry IV, D, Schuchter, L, Van Belle, TJ, Albelda, S, Tahin, P, Herlyn, M & Elder, DE 1999, 'Progression-related expression of β3 integrin in melanomas and nevi', Human Pathology, vol. 30, no. 5, pp. 562-567. https://doi.org/10.1016/S0046-8177(99)90202-2

    Progression-related expression of β3 integrin in melanomas and nevi. / Van Belle, Patricia A.; Elenitsas, Rosalie; Satyamoorthy, Kapaettu; Wolfe, Jonathan T.; Guerry IV, Dupont; Schuchter, Lynne; Van Belle, Timothy J.; Albelda, Stephen; Tahin, Paulo; Herlyn, Meenhard; Elder, David E.

    In: Human Pathology, Vol. 30, No. 5, 1999, p. 562-567.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Progression-related expression of β3 integrin in melanomas and nevi

    AU - Van Belle, Patricia A.

    AU - Elenitsas, Rosalie

    AU - Satyamoorthy, Kapaettu

    AU - Wolfe, Jonathan T.

    AU - Guerry IV, Dupont

    AU - Schuchter, Lynne

    AU - Van Belle, Timothy J.

    AU - Albelda, Stephen

    AU - Tahin, Paulo

    AU - Herlyn, Meenhard

    AU - Elder, David E.

    PY - 1999

    Y1 - 1999

    N2 - The expression of the βs integrin subunit was investigated in 130 fixed, paraffin-embedded specimens of human melanomas and nevi using two different monoclonal antibodies. Expression was not observed in melanocytes and was absent or low in most nevi. In primary melanomas, expression was absent or low in the nontumorigenic radial growth phase, which includes the classes of in situ and microinvasive melanomas. In contrast, expression was high in the tumorigenic or vertical growth phase compartment of many primary melanomas and in most metastatic melanomas. Expression patterns were similar with the two antibodies, SSA6 and SAP, and was membrane-related as well as cytoplasmically expressed. In those nevi that reacted locally, the reactivity tended to occur in the dermal component of necrotized nevi, and in Spitz nevi, where the reactivity was stronger and more diffuse. A few dysplastic nevi showed focal reactivity of the junctional component. These results are consistent with tumor progression-related expression of the β3 integrin, which is expressed in melanocytic tumors as the αvβ3 integrin, having affinity for matrix molecules, including vitronectin and fibronectin. In all melanomas, and in the subset of tumorigenic vertical growth phase melanomas, expression increased with thickness (P < .01). For this reason, and because ligation of this integrin has been shown in vitro to have several properties that may be related to the malignant phenotype, it is likely that expression of this marker may hove prognostic value. However, because of its consistent and strong expression in Spitz nevi, the diagnostic utility of this marker will likely be limited.

    AB - The expression of the βs integrin subunit was investigated in 130 fixed, paraffin-embedded specimens of human melanomas and nevi using two different monoclonal antibodies. Expression was not observed in melanocytes and was absent or low in most nevi. In primary melanomas, expression was absent or low in the nontumorigenic radial growth phase, which includes the classes of in situ and microinvasive melanomas. In contrast, expression was high in the tumorigenic or vertical growth phase compartment of many primary melanomas and in most metastatic melanomas. Expression patterns were similar with the two antibodies, SSA6 and SAP, and was membrane-related as well as cytoplasmically expressed. In those nevi that reacted locally, the reactivity tended to occur in the dermal component of necrotized nevi, and in Spitz nevi, where the reactivity was stronger and more diffuse. A few dysplastic nevi showed focal reactivity of the junctional component. These results are consistent with tumor progression-related expression of the β3 integrin, which is expressed in melanocytic tumors as the αvβ3 integrin, having affinity for matrix molecules, including vitronectin and fibronectin. In all melanomas, and in the subset of tumorigenic vertical growth phase melanomas, expression increased with thickness (P < .01). For this reason, and because ligation of this integrin has been shown in vitro to have several properties that may be related to the malignant phenotype, it is likely that expression of this marker may hove prognostic value. However, because of its consistent and strong expression in Spitz nevi, the diagnostic utility of this marker will likely be limited.

    UR - http://www.scopus.com/inward/record.url?scp=13044277567&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=13044277567&partnerID=8YFLogxK

    U2 - 10.1016/S0046-8177(99)90202-2

    DO - 10.1016/S0046-8177(99)90202-2

    M3 - Article

    VL - 30

    SP - 562

    EP - 567

    JO - Human Pathology

    JF - Human Pathology

    SN - 0046-8177

    IS - 5

    ER -